Kauppila A, Ylikorkala O
Clin Endocrinol (Oxf). 1982 Dec;17(6):617-23. doi: 10.1111/j.1365-2265.1982.tb01635.x.
Pituitary secretion of PRL and TSH is under the control of inhibitory dopaminergic and stimulatory TRH-mediated mechanisms. To evaluate the relationships between these regulatory systems, ten healthy women were treated with oral TRH (20 mg twice daily), a dopamine blocking drug, metoclopramide (MC) (10 mg t.d.s.) or placebo for 1 week (from 8th to 14th cycle day). Serum concentrations of PRL, TSH, T3 and T4 were determined before, at the end, and 3 days after the treatments. In addition, PRL and TSH responses to i.v. TRH (200 micrograms) or MC (10 mg) were studied at the end of the oral treatments. Oral TRH treatment was accompanied by increases in basal T3 and T4 concentrations, no change in PRL, and a decrease in TSH 3 days after the end of treatment. Oral TRH did not modify the PRL response to i.v. MC while it eliminated the TSH response to i.v. MC, possibly because of elevated concentrations of thyroid hormones. Oral MC treatment raised the concentrations of PRL, T3 and T4, and also potentiated the PRL response to i.v. TRH, whereas the TSH response remained unaltered. These results demonstrate that dopaminergic and TRH-mediated mechanisms are related in the control of PRL and TSH secretions, perhaps directly or through thyroid hormones.
垂体分泌催乳素(PRL)和促甲状腺激素(TSH)受抑制性多巴胺能机制和刺激性促甲状腺激素释放激素(TRH)介导机制的控制。为了评估这些调节系统之间的关系,对10名健康女性进行了为期1周(月经周期第8天至第14天)的口服TRH(每日两次,每次20mg)、多巴胺阻断药物甲氧氯普胺(MC)(每日三次,每次10mg)或安慰剂治疗。在治疗前、治疗结束时及治疗后3天测定血清PRL、TSH、T3和T4浓度。此外,在口服治疗结束时研究了静脉注射TRH(200μg)或MC(10mg)后PRL和TSH的反应。口服TRH治疗后,基础T3和T4浓度升高,PRL无变化,治疗结束后3天TSH降低。口服TRH未改变PRL对静脉注射MC的反应,但消除了TSH对静脉注射MC的反应,这可能是由于甲状腺激素浓度升高所致。口服MC治疗使PRL、T3和T4浓度升高,还增强了PRL对静脉注射TRH的反应,而TSH反应保持不变。这些结果表明,多巴胺能机制和TRH介导机制在PRL和TSH分泌的控制中相互关联,可能是直接关联或通过甲状腺激素关联。